(HealthDay News) — The UroLift system has been approved by the U.S. Food and Drug Administration to treat low or blocked urine flow in men aged 50 and older who have an enlarged prostate.
The new device, which helps prevent the prostate from pressing on the urethra, was evaluated in clinical studies involving 274 men between the ages of 49 and 86. Participants given the device reported fewer symptoms of enlarged prostate and a better quality of life, the FDA said.
The most common adverse reactions included pain or burning during urination, blood in the urine, and incomplete emptying of the bladder.
Continue Reading
The UroLift system is produced by NeoTract Inc., based in Pleasanton, Calif.
Enjoying our content?
Thanks for visiting Oncology Nurse Advisor. We hope you’re enjoying the latest clinical news, full-length features, case studies, and more.
You’ve viewed {{metering-count}} of {{metering-total}} articles this month. If you wish to read unlimited content, please log in or register below. Registration is free.
{{login-button}} {{register-button}}
Log in to continue reading this article.
Don’t miss out on today’s top content on Oncology Nurse Advisor. Register for free and gain unlimited access to:
- Clinical Updates
- Evidence-Based Guidance
- Conference Coverage
- Full-Length Features
- Drug Monographs
- And More
{{login-button}} {{register-button}}
Want to read more?
Please login or register first to view this content.